Dynasil Corporation of America ("Dynasil" or the "Company") (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced the appointment of Nirmal Parikh, a 20-year industry expert to the position of Vice President, Marketing.

Dynasil Corporation of America (NASDAQ: DYSL) today announced its Hilger Crystals subsidiary of Margate, Kent, UK has achieved ISO 9001:2015 certification. Hilger is a leading manufacturer of synthetic crystals for the security, defense, and medical industries and specializes in custom developed scintillators and imaging arrays.

Radiation Monitoring Devices (RMD) was featured on the U.S. Department of Energy Office of Science website for its work on portable solid state detectors which allow first responders to identify a wide range of radioactive sources.

Presentation given at the Dynasil Corporation of America Annual Meeting on February 22, 2018. Presenation by Peter Sulick, CEO and Chairman Dynasil Corporation, Linda Zuckerman Ph.D. CEO Xcede Technologies, Kanai Shah Ph.D., President RMD, and Gary Bishop Ph.D. V.P. of Photonics Dynasil Corporation.

Newton, Mass., January 17, 2018 – Dynasil Corporation of America (NASDAQ: DYSL) today announced its subsidiaries EMF Corporation and Optometrics Corporation have completed their development of the first in a series of Infrared High Efficiency Anti-Reflective (HEAR) thin film coatings for the eight to twelve micron spectral region.

Newton, MA. Jan 11, 2018 – The Xcede Patch clinical trial dossier was submitted today to the Medical Ethical Review Committee (MREC) Universitair Medisch Centrum Groningen (Netherlands), in anticipation of a first-in-human clinical trial. The clinical trial, which outlines the treatment of up to 30 patients undergoing various types of liver resection, will take place at two major liver surgery centers in The Netherlands. Subject to the MREC approvals, the Company anticipates that patients will be treated with the Xcede Patch in the Netherlands in early 2018.

Newton, MA, August 10, 2017 –Dynasil Corporation of America (NASDAQ: DYSL) today
announced that its contract research subsidiary, RMD Inc., has received two Phase II grants
totaling $2.1 million under the National Institute of Health and NASA’s Small Business Innovation
Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

Newton, MA, August 2, 2017 –Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received three Phase II grants totaling $3.5 million under the Department of Energy’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

Dynasil is very excited to announce that key scintillation crystal research done by its subsidiary RMD is included in the payload of CASIS Orbital ATK CRS-7 en-route to the International Space Station

Dynasil hosted its annual meeting on February 23rd, 2017 in Watertown, MA on the campus of its RMD subsidiary. The meeting included presentations by President and CEO, Peter Sulick, President of RMD, Dr. Kanai Shah and CEO of Xcede, Dr. Linda Zuckerman.